Newer Biomarkers in Heart Failure

Sachin Gupta; Mark H Drazner; James A de Lemos

doi:10.1016/j.hfc.2009.04.004

Newer Biomarkers in Heart Failure

Sachin Gupta, Mark H Drazner, James A de Lemos

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

Original language	English (US)
Pages (from-to)	579-588
Number of pages	10
Journal	Heart Failure Clinics
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/j.hfc.2009.04.004
State	Published - Oct 2009

Keywords

Adipokines
Biomarkers
Chromogranin A
Cystatins
Galectins
Heart failure
Osteoprotegerin

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2009.04.004

Cite this

@article{73ef840cd5b1455b99210fddbabfc0c6,

title = "Newer Biomarkers in Heart Failure",

abstract = "The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.",

keywords = "Adipokines, Biomarkers, Chromogranin A, Cystatins, Galectins, Heart failure, Osteoprotegerin",

author = "Sachin Gupta and Drazner, {Mark H} and {de Lemos}, {James A}",

year = "2009",

month = oct,

doi = "10.1016/j.hfc.2009.04.004",

language = "English (US)",

volume = "5",

pages = "579--588",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Newer Biomarkers in Heart Failure

AU - Gupta, Sachin

AU - Drazner, Mark H

AU - de Lemos, James A

PY - 2009/10

Y1 - 2009/10

N2 - The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

AB - The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

KW - Adipokines

KW - Biomarkers

KW - Chromogranin A

KW - Cystatins

KW - Galectins

KW - Heart failure

KW - Osteoprotegerin

UR - http://www.scopus.com/inward/record.url?scp=67650588131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650588131&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2009.04.004

DO - 10.1016/j.hfc.2009.04.004

M3 - Review article

C2 - 19631181

AN - SCOPUS:67650588131

SN - 1551-7136

VL - 5

SP - 579

EP - 588

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 4

ER -

Newer Biomarkers in Heart Failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this